Financial reports
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2023 Q2
Quarterly report
16 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Regulation FD Disclosure
18 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
8-K/A
Departure of Directors or Certain Officers
30 Oct 23
8-K
Departure of Directors or Certain Officers
16 Oct 23
8-K
Departure of Directors or Certain Officers
11 Oct 23
8-K
Departure of Directors or Certain Officers
7 Sep 23
8-K
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
24 Jul 23
8-K
Material Modifications to Rights of Security Holders
20 Jul 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
21 Jul 23
8-A12B
Registration of securities on exchange
19 Jul 23
S-1/A
IPO registration (amended)
14 Jul 23
S-1/A
IPO registration (amended)
3 Jul 23
S-1/A
IPO registration (amended)
8 May 23
S-1
IPO registration
14 Feb 23
S-1/A
IPO registration (amended)
27 Mar 19
S-1/A
IPO registration (amended)
25 Feb 19
S-1
IPO registration
29 Jan 19